28 May 2021

Appointment of new Chief Executive Officer

Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that Greg Madison has been appointed as Chief Executive Officer (CEO) with effect from Tuesday, 1 June 2021.

Greg has an excellent commercialisation track record and, in particular, he has deep knowledge and previous experience in the US iron deficiency marketplace.

For full details click here.

Back to News